torcetrapib Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Torcetrapib was a drug being developed to treat hypercholesterolemia and prevent cardiovascular disease. Its development was halted in 2006 when phase III studies showed excessive all-cause mortality in the treatment group receiving a combination of atorvastatin (Lipitor) and torcetrapib.   Wikipedia

Chemistry

  • SMILES: CCOC(=O)N1c2ccc(C(F)(F)F)cc2[C@@H](N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)C(=O)OC)C[C@H]1CC
  • InChIKey: CMSGWTNRGKRWGS-NQIIRXRSSA-N
  • Mol. Mass: 600.48
  • ALogP: 8.2
  • ChEMBL Molecule:
    torcetrapib  
More Chemistry

Pharmacology

Alternative names

cp529414 | cp 529414 | cp 529,414 | cp-529414 | cp-529,414 | cp529,414 | torcetrapib

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Coronary Artery Disease (Phase 3)

Coronary Disease (Phase 3)

Diabetes Mellitus (Phase 3)

Dyslipidemias (Phase 3)

Hypercholesterolemia (Phase 3)

Hyperlipidemias (Phase 3)

Hyperlipoproteinemia Type II (Phase 3)

Hyperlipoproteinemia Type III (Phase 3)

Hyperlipoproteinemia Type IV (Phase 3)

Hypertriglyceridemia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue